Metraipolis › archive › dc_4e34ef21b806
Effectiveness and Safety of Lenvatinib and Everolimus after Immune Checkpoint Inhibitors in Metastatic Renal Cell Cancer: A Systematic Review — Europe PMC PMID:41502513
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41502513
- DOI
- 10.32604/or.2025.070523
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T07:58:29.336Z
- SHA-256 of the archived text
f78a5e4fa6386eac730376718ea158e1c938b8dda44eaee52a3af8667ee5b53c- Stable URL of this page
https://metraipolis.com/documento/dc_4e34ef21b806
How to cite
Effectiveness and Safety of Lenvatinib and Everolimus after Immune Checkpoint Inhibitors in Metastatic Renal Cell Cancer: A Systematic Review — Europe PMC PMID:41502513 — Europe PMC (en), https://europepmc.org/article/MED/41502513 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_4e34ef21b806 (Metraipolis archive dc_4e34ef21b806, sha256 f78a5e4fa6386eac730376718ea158e1c938b8dda44eaee52a3af8667ee5b53c)
BibTeX
@misc{dc4e34ef21b806,
title = {Effectiveness and Safety of Lenvatinib and Everolimus after Immune Checkpoint Inhibitors in Metastatic Renal Cell Cancer: A Systematic Review — Europe PMC PMID:41502513},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41502513},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_4e34ef21b806; sha256 f78a5e4fa6386eac730376718ea158e1c938b8dda44eaee52a3af8667ee5b53c},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41502513. Agents can read the archived copy with the MCP tool read_document.